A matter of controversy: is radioiodine therapy favorable in differentiated thyroid carcinoma?
M Schmidt, R Görges, A Drzezga… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Radioiodine therapy is a matter of controversy because different opinions exist about its use
for differentiated thyroid carcinoma. The following article sheds light on the different opinions …
for differentiated thyroid carcinoma. The following article sheds light on the different opinions …
Radioiodine therapy in differentiated thyroid cancer–a matter of controversy–PRO Radioiodine
M Schmidt, R Görges, A Drzezga… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Radioiodine therapy is a matter of controversy as different opinions exist towards its use in
patients with differentiated thyroid carcinoma. The following article sheds light on different …
patients with differentiated thyroid carcinoma. The following article sheds light on different …
Current controversies in risk-adapted therapy in differentiated thyroid cancer: Is less (therapy) really more?
A Kurtaran, B Schmoll-Hauer, C Tugendsam - Wiener Medizinische …, 2020 - Springer
In recent years, there has been worldwide a significant (relative) increase in “small” thyroid
cancer (pT1= tumor size of≤ 10 mm), which has now reached a plateau. This fact and the …
cancer (pT1= tumor size of≤ 10 mm), which has now reached a plateau. This fact and the …
Ablative Radioiodtherapie des Schilddrüsenkarzinoms
M Dietlein, A Drzezga - Nuklearmedizin-NuclearMedicine, 2018 - thieme-connect.com
119 cherzeller von I-131 aus dem Bloodpool resultiert, wird die Applikationsform oral versus
intravenös keine geeignete Strategie zur Strahlenminimierung sein. So bleibt die Frage, bei …
intravenös keine geeignete Strategie zur Strahlenminimierung sein. So bleibt die Frage, bei …
[引用][C] Ablative Radioiodtherapie des Schilddrüsenkarzinoms
L nach der Radioiodtherapie - Nuklearmedizin, 2018